Observational study of cancer drugs for breast and gynecologic cancers in routine care
Compares drug effects and side effects in breast and gynecologic cancer patients.
Key facts
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Where
- Bologna, ItalySee the site
- Trial code
- Registry title
- Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 22 Mar 2024
- Expected to end
- 31 Dec 2030
- Type of study
- Observational, 2 groups
- Treatments tested
- Oncologic drugs administered for treatment of breast cancer
- Oncologic drug administered for treatment of gynecologic cancer
- Record updated
- 30 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with breast cancer or gynecologic cancer who have had drug treatment since January 2010. It follows how well the drugs worked and what side effects they caused.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Breast cancer or gynecologic cancer, confirmed by tissue examination, either early stage or metastatic
- Earlier treatment
- Must have received treatment for breast cancer or gynecologic cancer since January 2010
Main reasons for not taking part
- The record lists no exclusion criteria
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic
- Patients who have received treatment for breast cancer or gynecologic cancer since January 2010
- Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data
Who cannot take part
- no exclusion criteria
Where in Italy
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyContact: Claudio Zamagni, MDTaking people
About the trial
What the trial wants to find out
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.
The 2 groups in the trial
- retrospective cohort
In this cohort data will be recorded retrospectively
Treatment: Oncologic drugs administered for treatment of breast cancer and Oncologic drug administered for treatment of gynecologic cancer
- prospective cohort
In this cohort data will be recorded prospectively
Treatment: Oncologic drugs administered for treatment of breast cancer and Oncologic drug administered for treatment of gynecologic cancer
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Observational Study Evaluating the Efficacy and Tolerability of Anticancer Drug Therapies Adopted for the Treatment of Gynecologic and Breast Cancers in Clinical Practice Compared with the Results of Registration Studies
- Plain-language title
- Observational study of cancer drugs for breast and gynecologic cancers in routine careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 January 2025